1 study found for:    11979093 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
Conditions: T-Cell Peripheral Lymphoma;   Gamma Delta Hepatosplenic T-Cell Lymphoma;   Subcutaneous Panniculitis-Like T-Cell Lymphoma;   NK T-Cell Lymphoma
Interventions: Biological: Rituximab;   Drug: EPOCH;   Biological: Siplizumab

Indicates status has not been verified in more than two years